Skip to main content

Table 3 Robustness study

From: A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

Parameters

Changes done

Tenofovir

Darunavir

Emtricitabine

Cobicistat

Change in flow rate

 

Area*

Area*

Area*

Area*

0.9 mL

59,662

345,373

428,300

36,922

1 mL

62,377

343,268

410,983

37,868

1.1 mL

61,702

330,567

403,890

36,036

Organic composition in mobile phase

10%less

60,835

334,251

418,302

36,554

Actual

62,377

343,268

410,983

37,868

10% more

61,473

319,463

420,831

37,831

Detection wavelength

252 nm

59,870

325,549

408,822

37,402

254 nm

62,377

343,268

410,983

37,868

256 nm

61,352

338,546

412,297

36,451

% RSD

1.64

1.85

1.89

1.32

  1. *Average of three readings